Back in November, Actavis said it would invite two members of Allergan's board to join the ranks of the new company's directors in the wake of their $66 billion merger. And according to Reuters' sources, Allergan CEO David Pyott is one of them.
When GlaxoSmithKline's multibillion-dollar asset swap with Novartis closes this year, don't expect the British pharma giant to stop there, its CEO says--especially when it comes to consumer health.
Johnson & Johnson's Janssen unit has agreed to offer England's National Health Service a money-back guarantee on its hep C fighter Olysio, even as the treatment won approval from the cost watchdog there.
AbbVie has won European Commission approval for its oral hepatitis C cocktail, offering some positive news after some disappointments for the U.S. drugmaker in recent months. It also sets the stage for the drugmaker to take its marketing battle with Gilead Sciences to another continent.
Gilead Sciences is gaining ground in its hep C pricing battle with AbbVie. One week after the drugmaker joined forces with Anthem to make Harvoni the primary option for the PBM's 30 million patients, Gilead inked similar deals with Humana and Harvard Pilgrim, edging out its competitor and raising the stakes in the companies' ongoing war.
Earlier this week, once-skeptical Johnson & Johnson CEO Alex Gorsky seemed to be fully on-board pharma's slim-down bandwagon, telling presentation-watchers at the JP Morgan Healthcare Conference he was willing to jettison pieces of the J&J puzzle if they didn't present a "path to achieving leadership." Now, he's followed up with another divestment that will send U.S. rights to pain med Nucynta to California's Depomed.
Gilead Sciences said that an India patent office ruling on hepatitis C drug Sovaldi (sofosbuvir) only affects an application covering part of the active ingredient and that the larger validity of the uniqueness of the product remains intact as does a path-breaking patient access for the drug.
Pfizer has written doctors in the U.K. warning them not to prescribe Lyrica knockoffs to treat neuropathic pain. Seems the company still has a live patent covering Lyrica's use against that type of nerve pain.
Sounds like Impax Laboratories' October pickup of Lineage Therapeutics and Tower Holdings was just the beginning of an M&A streak. The company is "aggressively hunting" further buyouts and is in ongoing talks with multiple targets, its CEO says.
Sanofi and Regeneron are hard at work on a number of promising monoclonal antibodies, but Sanofi needs more manufacturing capacity to produce them. Instead of building its own like some of its peers, the French company has struck a deal to tap into a Boehringer Ingelheim plant in Germany.
India's intellectual-property police nixed a key patent on Gilead Sciences' hepatitis C drug Sovaldi, opening the door for cheap generic copies from domestic drugmakers such as Natco Pharma. It's the latest blow to a multinational drugmaker's ambitions in India, which remains one of the fastest-growing drug markets in the world.
Boehringer Ingelheim has been struggling under the weight of slumping sales and patent expirations for some of its top products, shedding jobs and unloading assets to lighten its load. The German company could be set to slim down further, as it considers selling its U.S.-based generics unit for up to £2 billion ($2.33 billion) to focus on developing new drugs.
China's FDA has awarded marketing approval of the world's first Sabin strain inactivated polio vaccine, marking a milestone as well for the Institute of Medical Biology of the Academy of Medical Sciences.
Soon after CEO Pascal Soriot took over at AstraZeneca in 2012, he declared Brilinta to be a big opportunity for growth. That was a surprise, given the blood thinner's laggardly sales since its 2011 launch. But Soriot put cash on the table to back up his hunch, with plans for big outcomes studies, stepped-up advertising, and an expanded cadre of sales reps.
Racking up points for filling prescriptions or taking home prizes for sticking with meds might sound like a far-flung concept. But according to a new study from HealthPrize Technologies, the technique actually works.
Now that Express Scripts--and rival CVS Health--have cost-slashing exclusives with hep C drugmakers, the activist PBM says it's ready to take on the forthcoming class of cholesterol-fighters known as PCSK9 inhibitors, too.
Gilead Sciences was dealt a stinging blow from Germany's price watchdog IQWiG over its cancer-fighting drug Zydelig (idealisib), as the cost-effectiveness gatekeeper found the drug has no added benefit for patients with chronic lymphocytic leukemia compared with existing therapies.
SAN FRANCISCO--Actavis may be a big pharma now that it's joining hands with Allergan, but it's not a Big Pharma, CEO Brent Saunders insists. The merger partners are taking the term "growth pharma" and running with it as they set out to differentiate themselves from the industry's slow-growing stalwarts.
SAN FRANCISCO--Here's a game to play at the annual JP Morgan Healthcare Conference. Attend presentations by executives at Big Pharma, Big Biotech, and slightly less big biopharma companies, hoping to hear something new and different they're willing to say in public. Here's the latest from FiercePharma's notebook.